Camlin Fine Sciences Ltd - Stock Valuation and Financial Performance

BSE: 532834 | NSE: CAMLINFINE | Chemicals | Small Cap

Camlin Fine Sciences Share Price

105 -1.15 -1.08%
as on 12-Jul'24 16:01

DeciZen - make an informed investing decision on Camlin Fine Sciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Camlin Fine Sciences stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
1,749.5 Cr.
52-wk low:
80
52-wk high:
186.3

Is Camlin Fine Sciences Ltd an attractive stock to invest in?

1. Is Camlin Fine Sciences Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Camlin Fine Sciences Ltd is a below average quality company.

2. Is Camlin Fine Sciences Ltd undervalued or overvalued?

The key valuation ratios of Camlin Fine Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Camlin Fine Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Camlin Fine Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Camlin Fine Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Camlin Fine Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 18.8%16.8%5.7%0.5%4.1%6.1%5.3%4.8%6.5%-0.8%-
Value Creation
Index
0.30.2-0.6-1.0-0.7-0.6-0.6-0.7-0.5-1.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 431412325403548580600686789773773
Sales YoY Gr.--4.3%-21.2%24.1%36.1%5.8%3.5%14.2%15.2%-2.1%-
Adj EPS 2.82.90.2-1.30.71.71.11.22-3.2-3.1
YoY Gr.-3.2%-93.7%-833.3%NA130.6%-31.9%9.7%59.7%-261.6%-
BVPS (₹) 10.212.516.825.526.83132.4374041.941.9
Adj Net
Profit
26.627.71.9-16.18.820.214.419.431.1-53.6-51
Cash Flow from Ops. 26.450.9-30.1-5.2-44.673.92646.818.582.1-
Debt/CF from Ops. 5.13.1-8.1-41.7-74.514.39.632.66-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 6.7%7.1%8.8%-2.1%
Adj EPS -201.6%-234.8%-241.5%-261.6%
BVPS17%9.3%8.9%4.8%
Share Price 9.2% 12.5% -21.6% -33%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
30.525.41.3-6.32.65.63.43.75-7.9-7.3
Op. Profit
Mgn %
14.516.58.51.1610.412.411.616.84.33.5
Net Profit
Mgn %
6.26.70.6-41.63.52.42.83.9-6.9-6.7
Debt to
Equity
1.41.31.40.710.90.90.810.70.3
Working Cap
Days
200232322338305315338344366415182
Cash Conv.
Cycle
689618118015216216816519323360

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.70

Return on Equity is Poor

Sales growth has been subdued in last 3 years 8.82%

Sales growth is not so good in last 4 quarters at -0.77%

Latest Financials - Camlin Fine Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) -3.1 -5.5
TTM Sales (₹ Cr.) 773 1,613
BVPS (₹.) 41.9 48.1
Reserves (₹ Cr.) 685 789
P/BV 2.49 2.17
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 80.00 / 186.25
All Time Low / High (₹) 1.94 / 230.80
Market Cap (₹ Cr.) 1,749
Equity (₹ Cr.) 16.8
Face Value (₹) 1
Industry PE 56.6

Management X-Ray of Camlin Fine Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.0012.4312.43
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Camlin Fine Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales431412325403548580600686789773
Operating Expenses 370345301399515519534606657741
Manufacturing Costs3337293442506496157169
Material Costs279244204303409389378395366444
Employee Cost 18192221232839536066
Other Costs 41444741425254637562
Operating Profit 61682343360667913233
Operating Profit Margin (%) 14.1%16.4%7.2%1.0%6.0%10.4%10.9%11.6%16.8%4.2%
Other Income 24141314278202921
Interest 21222626233138366262
Depreciation 101012991119273349
Exceptional Items 0-5000-3-100-2
Profit Before Tax 32350-181441153667-60
Tax 691-431171019-8
Profit After Tax 2626-1-14113182648-51
PAT Margin (%) 6.0%6.2%-0.2%-3.5%2.0%5.3%1.4%3.8%6.0%-6.6%
Adjusted EPS (₹)2.72.7-0.1-1.20.92.50.71.73.0-3.1
Dividend Payout Ratio (%)17%17%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 98121174309325376413580628702
Share Capital 10101012121213161617
Reserves 88111164297313364400564612685
Minority Interest0000000000
Debt124146234215310331363438512456
Long Term Debt27201114111113163258292222
Short Term Debt98126223200199218201180220233
Trade Payables948036114106133193212249284
Others Liabilities 30362938395197116205130
Total Liabilities 3463824746767808911,0671,3461,5941,572

Fixed Assets

Gross Block1241608890109131348381682723
Accumulated Depreciation617111202937567799147
Net Fixed Assets638976708094292304583577
CWIP 01142068198182072831
Investments 5744148697474828280
Inventories9011811611510997131142252255
Trade Receivables12498131211262323368441526492
Cash Equivalents 12131311691382561014
Others Assets52557810112292102113113123
Total Assets 3463824746767808911,0671,3461,5941,572

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 2651-30-5-457426471982
PBT 32350-181441153667-60
Adjustment 303329191922655576140
Changes in Working Capital -25-11-52-6-7412-44-43-11720
Tax Paid -10-6-70-4-1-10-1-7-18
Cash Flow From Investing Activity -23-49-31-116-3-66-88-172-115-52
Capex -23-37-6-15-52-115-39-189-131-41
Net Investments -1-2-26-1024344-502829-8
Others 1-1021552-11-12-3
Cash Flow From Financing Activity -5-16112065-268012978-34
Net Proceeds from Shares 1358148000111
Net Proceeds from Borrowing 00-14-2-10-2468891-1
Interest Paid -22-22-23-24-31-39-40-31-39-47
Dividend Paid -3-4-50000000
Others 192245-21061674712613
Net Cash Flow -100-117-18183-18-4
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)29.6723.55-0.54-5.873.388.762.15.217.87-7.73
ROCE (%)23.9922.047.361.656.1910.596.97.7211.280.18
Asset Turnover Ratio1.41.160.790.70.750.690.610.570.540.49
PAT to CFO Conversion(x)11.96N/AN/A-4.092.393.251.810.4N/A
Working Capital Days
Receivable Days8996124154158184210215224240
Inventory Days57901271047565707391120
Payable Days1011291049198112157187230219

Camlin Fine Sciences Ltd Stock News

Camlin Fine Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Camlin Fine Sciences on 12-Jul-2024 16:01 is ₹105.0.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Jul-2024 16:01 the market cap of Camlin Fine Sciences stood at ₹1,749.5.
The latest P/E ratio of Camlin Fine Sciences as of 12-Jul-2024 16:01 is 0.00.
The latest P/B ratio of Camlin Fine Sciences as of 12-Jul-2024 16:01 is 2.49.
The 52-week high of Camlin Fine Sciences is ₹186.2 and the 52-week low is ₹80.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Camlin Fine Sciences is ₹773.3 ( Cr.) .

About Camlin Fine Sciences Ltd

Camlin, the corporate group, was established in 1931 and is a pioneer in art and stationery material in India. Camlin diversified into Pharmaceuticals and Fine Chemicals two decades ago. The Fine Chemical Division of Camlin got de-merged into a separate company named as Camlin Fine Chemicals on 22nd December 2006. The entire management team and employees of Camlin Fine Chemicals Division are now a part of the independent legal entity formed under the Indian Companies Act 1956. In 2011
Company changed its name from Camlin Fine Chemicals Ltd. to Camlin Fine Sciences Ltd. 

Camlin Fine Chemicals is the world's second largest manufacturer and marketer of food grade antioxidants TBHQ and BHA. Its mission is to be the largest food antioxidant and ingredient manufacturer worldwide. Their facilities are HACCP and ISO 9001 : 2000 certified.

Product Range:

a) Food Ingredients –

Antox TBHQ (HACCP Certified) FCC V / FAO / WHO (Tertiary Butyl Hydroquinone)

Antox BHA (HACCP Certified) FCC V / FAO / WHO / EEC ( Butyl Hydroxy Anisole)

b) Sweetener -

Sucralose FCC V

c) Active Pharmaceutical Ingredients -

  • Miconazole Nitrate B.P. / USP
  • Clotrimazole B.P. / USP
  • Amlodipine Besilate E.P
  • Amlodipine Salts
  • Advance intermediate of Amlodipine
  • Intermediate of Miconazole Nitrate

d) Super Absorbent Polymer

Subsidiary Details:

  • Chemolutions Chemicals: Specialty Chemical Intermediates
  • Sangam Laboratories: Nutraceuticals
  • Fine Renewable Energy.
  • Fine LifeStyle Brands: Luxury Fashion Brands

On 6th June 2008 - The company entered into a joint venture, on 51:49 basis, with US based Viachem LLC, to set up a joint venture company under the name Dulcette Technologies for marketing Sucralose, Aspartame, and Acesulfame-K, and their belnds in USA, Canada, and Maxico.

On 7th July 2008 - The Board of Directors of the company at its meeting held on 29th July 2008, approved the proposal for setting up a joint venture company with Pagoda Advisors and their associates.

As per the deal, Camlin Fine Chemicals will get 51% of the equity of the proposed new company and the rest 49% will be owned by Pagoda Advisors and their associates.The proposed new company will focus on the retail of luxury/premium brands in India by setting up stores in all stores in all major metros and cities in India by itself and through franchisees.

On 25th February 2008:  Camlin Fine Chemicals acquired 60% equity stake in Sangam Laboratories, a Small Scale Unit manufacturing Nutraceuticals and Drug Intermediates at Tarapur.

On 12th February 2008 - The company inked a joint venture deal with US based Advanced Aerospace Technologies to manufacture and market speciality fine chemicals primarily to cater to European and U.S markets.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.